Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: a case report.

Lin B, Huang Q, Weng L, Lin L

Frontiers in medicine12 Sept 2025

PMID41020234PMCIDPMC12463625DOI10.3389/fmed.2025.1684204PepBankPUB-41020234

Summary

This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD). The patient presented with metabolic dysregulation, severe psoriatic lesions, and hepatic steatosis. Initial therapies, including acitretin and topical agents, failed to yield clinical improvement. Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment. At 24 weeks, the patient exhibited significant improvements: HbA1c decreased from 9.8 to 7.2%, body weight reduced by 6 kg, liver enzymes returned to normal ranges, and PASI declined to 6.2. Treatment was well-tolerated with no severe adverse events.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesEfficacy outcome
In a 49-year-old man with T2DM, psoriasis and MASLD, HbA1c fell from 9.8 to 7.2% at 24 weeks of semaglutide.
In plain wordsIn one man with diabetes, psoriasis and fatty liver, blood sugar control improved over 24 weeks on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.25 mg/week titrated to 1 mg/week · 24 weeksAs given in this study (human).
Measurements
HbA1c baseline
9.8%
baseline
HbA1c at 24 weeks
7.2%
24 weeks
Source sentences
Summary
HbA1c decreased from 9.8 to 7.2%
2 context sentences(design, population, supporting numbers)
Summary · context
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary · context
Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment.
Show in the study text Report a problemFND-4102023401
02HumanCase report or seriesEfficacy outcome
In a 49-year-old man with T2DM, psoriasis and MASLD, body weight fell by 6 kg at 24 weeks of semaglutide.
In plain wordsOne man with diabetes, psoriasis and fatty liver lost 6 kg over 24 weeks on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
0.25 mg/week titrated to 1 mg/week · 24 weeksAs given in this study (human).
Measurements
Body weight change
−6 kg
24 weeks
Source sentences
Summary
body weight reduced by 6 kg
2 context sentences(design, population, supporting numbers)
Summary · context
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary · context
Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment.
Show in the study text Report a problemFND-4102023402
03HumanCase report or seriesEfficacy outcome
In a 49-year-old man with T2DM, psoriasis and MASLD, liver enzymes returned to normal ranges at 24 weeks of semaglutide.
In plain wordsIn one man with diabetes, psoriasis and fatty liver, liver enzyme tests returned to normal after 24 weeks on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLiver enzymes
Study
n = 1
Outcome group
Liver fat and liver function · Liver
Studied dose
0.25 mg/week titrated to 1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
liver enzymes returned to normal ranges
2 context sentences(design, population, supporting numbers)
Summary · context
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary · context
Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment.
Show in the study text Report a problemFND-4102023403
04HumanCase report or seriesEfficacy outcome
In a 49-year-old man with T2DM, psoriasis and MASLD, PASI fell from 22 to 6.2 at 24 weeks of semaglutide.
In plain wordsOne man with diabetes, psoriasis and fatty liver had much milder psoriasis after 24 weeks on semaglutide.
Peptide
Semaglutide
Outcome
DecreasePsoriasis severity (PASI)
Study
n = 1
Outcome group
Skin and hair · Skin and wound
Studied dose
0.25 mg/week titrated to 1 mg/week · 24 weeksAs given in this study (human).
Measurements
PASI baseline
22 points
baseline
PASI at 24 weeks
6.2 points
24 weeks
Source sentences
Summary
PASI declined to 6.2.
2 context sentences(design, population, supporting numbers)
Summary · context
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary · context
Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment.
Show in the study text Report a problemFND-4102023404
05HumanCase report or seriesSafety outcome
In a 49-year-old man treated with semaglutide, treatment was well tolerated with no severe adverse events.
In plain wordsOne man tolerated semaglutide well, with no severe side effects reported.
Peptide
Semaglutide
Outcome
No significant changeAdverse events
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
0.25 mg/week titrated to 1 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
Treatment was well-tolerated with no severe adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary · context
Semaglutide was initiated at 0.25 mg/week, titrated to 1 mg/week over 12 weeks, alongside metformin dose adjustment.
Show in the study text Report a problemFND-4102023405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.